155
Participants
Start Date
September 15, 2023
Primary Completion Date
February 7, 2024
Study Completion Date
February 19, 2024
K-757 120 mg BID and K-833 100 mg BID
"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8.~Both administered orally."
K-757 120 mg BID and matching placebo to K-833
"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22.~Both administered orally."
Matching placebo to K-757 and matching placebo to K-833
Both administered orally.
Rochester Clinical Research, Rochester
Capital Area Research, LLC, Camp Hill
Reading Hospital Clinical Trials Office, West Reading
MedStar Health Research Institute, Hyattsville
Washington Center for Weight Management and Research, Inc., Arlington
Charlottesville Medical Research, Charlottesville
Health Research of Hampton Roads, Inc, Newport News
Medication Management, LLC (PharmQuest), Greensboro
Wilmington Health (Accellacare of Wilmington), Wilmington
Spartanburg Medical Research, Spartanburg
Clinical Research Atlanta, Stockbridge
L-MARC Research Center, Louisville
Family Practice Center of Wadsworth, Inc dba New Venture Medical Research, Wadsworth
Quest Research Institute, Farmington Hills
Cotton O'Neil Clinical Research Center, Topeka
AMR Norman, Norman
North Hills Family Medicine/North Hills Medical Research, North Richland Hills
Clinical Trials of Texas, LLC, San Antonio
Headlands Research - Brownsville, Brownsville
Artemis Institute for Clinical Research, LLC, San Diego
Summit Headlands LLC, Portland
ActivMed Practices and Research, LLC, Portsmouth
Lead Sponsor
Kallyope Inc.
INDUSTRY